Free tool
FAERS Monitor: Propylthiouracil
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 006188 or its brand name (Propylthiouracil, Propylthiouracil). Reports on generic versions are filed under their own applications.
Reports
2,081
Serious
1,801
87% of reports
Hospitalization
946
Death reported
181
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective198
- off label use153
- hyperthyroidism140
- foetal exposure during pregnancy119
- nausea88
- anti-neutrophil cytoplasmic antibody positive vasculitis87
- exposure during pregnancy85
- maternal exposure during pregnancy76
- hypotension71
- agranulocytosis61
- pyrexia61
- fatigue59
- vomiting57
- product use in unapproved indication56
- cardiac arrest55
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 45 |
| 2005 | 39 |
| 2006 | 32 |
| 2007 | 47 |
| 2008 | 35 |
| 2009 | 30 |
| 2010 | 51 |
| 2011 | 104 |
| 2012 | 60 |
| 2013 | 47 |
| 2014 | 79 |
| 2015 | 78 |
| 2016 | 75 |
| 2017 | 72 |
| 2018 | 122 |
| 2019 | 137 |
| 2020 | 109 |
| 2021 | 97 |
| 2022 | 102 |
| 2023 | 188 |
| 2024 | 231 |
| 2025 | 205 |
| 2026 | 96 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,078 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anti-neutrophil cytoplasmic antibody positive vasculitisSignal | 87 | 368.7 | 299.0 | 30,432 |
| hyperthyroidismSignal | 140 | 98.7 | 84.0 | 13,322 |
| agranulocytosisSignal | 61 | 33.3 | 26.0 | 1,873 |
| foetal exposure during pregnancySignal | 119 | 14.8 | 12.4 | 1,523 |
| exposure during pregnancySignal | 85 | 13.8 | 11.2 | 1,001 |
| maternal exposure during pregnancySignal | 76 | 8.6 | 6.9 | 506 |
| cardiac arrestSignal | 55 | 6.7 | 5.2 | 264 |
| hypotensionSignal | 71 | 3.6 | 2.8 | 131 |
| product use in unapproved indicationSignal | 56 | 2.3 | 1.8 | 40 |
| pyrexia | 61 | 1.8 | 1.4 | 20 |
| off label use | 153 | 1.8 | 1.5 | 52 |
| drug ineffective | 198 | 1.5 | 1.3 | 37 |
| vomiting | 57 | 1.2 | 0.9 | 2 |
| nausea | 88 | 1.1 | 0.9 | 1 |
| fatigue | 59 | 0.8 | 0.6 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.